Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lacticaseibacillus rhamnosus R3
- Development stage
- Preclinical
- Lead developer
- California State University, Fullerton
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
Lacticaseibacillus rhamnosus R3 (also known as LR-R3) is a probiotic bacterium strain being investigated for its antagonistic activity against multidrug-resistant (MDR) and carbapenem-resistant Acinetobacter baumannii (CRAB) strains, as well as other ESKAPE pathogens. Developed by researchers at California State University, Fullerton (CSUF) and the Centro de Referencia para Lactobacilos (CERELA-CONICET) in Argentina, this strain produces bioactive compounds or metabolites that exert strong antimicrobial and bactericidal effects. In co-culture studies, L. rhamnosus R3 has been shown to alter iron and fatty acid metabolism in A. baumannii, disrupt cell viability, and increase the formation of outer membrane vesicles (OMVs) and nanotubes. It represents a promising non-antibiotic therapeutic alternative for combating nosocomial infections.
- Other names
- L. rhamnosus R3Lacticaseibacillus rhamnosus strain R3Lcb. rhamnosus R3
02
Targets
OmpA (Outer membrane protein A)
Beyond the preview
Go deeper on Lacticaseibacillus rhamnosus R3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lacticaseibacillus rhamnosus R3.